We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study of RR110 in Patients With Active Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00417391
Recruitment Status : Completed
First Posted : January 1, 2007
Last Update Posted : May 29, 2008
Sponsor:
Information provided by:
R&R Inc.

Brief Summary:
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics profile of 1 and 4 mg/kg/day RR110 administrated orally for 8 weeks in patients with active Crohn's disease.

Condition or disease Intervention/treatment Phase
Crohn's Disease Drug: RR110 (Tamibarotene) Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of RR110 in Patients With Active Crohn's Disease
Study Start Date : December 2006
Primary Completion Date : May 2008
Study Completion Date : May 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 mg RR110
1 mg RR110
Drug: RR110 (Tamibarotene)
1 mg RR110
Other Names:
  • Tamibarotene
  • Am80
Experimental: 4 mg RR110
4 mg RR110
Drug: RR110 (Tamibarotene)
4 mg RR110
Other Names:
  • Tamibarotene
  • Am80



Primary Outcome Measures :
  1. Change in Crohn's disease active index (CDAI) score [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Rate of clinical response as defined by CDAI decrease > 70 or 100 from baseline [ Time Frame: 8 weeks ]
  2. Rate of clinical remission as defined by CDAI < 150 [ Time Frame: 8 weeks ]
  3. Change in CRP, SAA, and fibrinogen levels, and IBDQ and CDEIS scores [ Time Frame: 10 weeks ]
  4. Safety parameters [ Time Frame: 10 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with CDAI score ranging from 220 to 450
  • Patients with CRP > 1 mg/dL
  • Patients who can be hospitalized at least 2 weeks after first administration

Exclusion Criteria:

  • Patients who have previously used anti-TNF antibody, cyclosporine, methotrexate or tacrolimus within 12 weeks of screening
  • Patients who have had surgical bowel resections within 4 weeks of screening
  • Patients who have previously used total parental nutrition or more than 900 kcal/day of enteral nutrition within 4 weeks of screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00417391


Locations
Japan
Toyohashi, Aichi, Japan
Sakura, Chiba, Japan
Sapporo, Hokkaido, Japan
Nishinomiya, Hyogo, Japan
Fujisawa, Kanagawa, Japan
Nakagami, Okinawa, Japan
Otsu, Shiga, Japan
Shinjuku, Tokyo, Japan
Sponsors and Collaborators
R&R Inc.
Investigators
Study Chair: Toshifumi Hibi, M.D., Ph.D. Keio University School of Medicine

Responsible Party: Miwako Ishido/Manager, R&R Inc.
ClinicalTrials.gov Identifier: NCT00417391     History of Changes
Other Study ID Numbers: 1101-01
First Posted: January 1, 2007    Key Record Dates
Last Update Posted: May 29, 2008
Last Verified: May 2008

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases